Matches in SemOpenAlex for { <https://semopenalex.org/work/W4254372635> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4254372635 endingPage "110" @default.
- W4254372635 startingPage "LB" @default.
- W4254372635 abstract "Abstract One of the most common genetic alterations in glioblastoma (30-40%) occurs in the tumor suppressor gene PTEN (phosphatase and tensin homolog), where loss of function has been mechanistically linked to increased tumor cell invasion, and to a lack of radio- and chemo-therapy response. To identify new drug compounds that target PTEN-deficient brain tumors we performed a high throughput drug screening using patient-derived GBM spheres and found that PTEN-deficient samples were highly sensitive to proteasome inhibitors. We confirmed PTEN dependency to proteasome inhibition by genetically overexpressing or deleting PTEN in GBM cells and established that the drug inhibition response relied on PTEN enzymatic activity. Additionally, proteasome inhibition specifically suppressed tumor growth and increased survival of mice orthotopically engrafted with human PTEN-null glioblastoma cancer stem cells. Mechanistically, we determined that PTEN-deficient cells were more sensitive to proteasome inhibition due to an increase in protein synthesis rate and loss of autophagy activity associated with activation of the PI3K/mTOR pathway. Finally, integrated in silico analysis of the Samsung Medical Center dataset corroborated that samples with PTEN/EGFR/PI3K alterations were significantly more sensitive to Carfilzomib, an FDA-approved proteasome inhibitor. This study reveals that PTEN-deficient cells are proteasome addictive and opens a new therapeutic opportunity to treat glioblastoma PTEN-deficient patients. Citation Format: Jorge A. Benitez, Darren Finlay, Alexandre Rosa-Campos, Jianhui Ma, Tomoyuki Koga, Kristiina Vuori, Frank Furnari. Proteasome addiction a new therapeutic opportunity to treat PTEN-deficient brain tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-110." @default.
- W4254372635 created "2022-05-12" @default.
- W4254372635 creator A5019398807 @default.
- W4254372635 creator A5036985768 @default.
- W4254372635 creator A5039505764 @default.
- W4254372635 creator A5047149762 @default.
- W4254372635 creator A5070673623 @default.
- W4254372635 creator A5074897884 @default.
- W4254372635 creator A5086979668 @default.
- W4254372635 date "2019-07-01" @default.
- W4254372635 modified "2023-09-27" @default.
- W4254372635 title "Abstract LB-110: Proteasome addiction a new therapeutic opportunity to treat PTEN-deficient brain tumors" @default.
- W4254372635 doi "https://doi.org/10.1158/1538-7445.am2019-lb-110" @default.
- W4254372635 hasPublicationYear "2019" @default.
- W4254372635 type Work @default.
- W4254372635 citedByCount "0" @default.
- W4254372635 crossrefType "journal-article" @default.
- W4254372635 hasAuthorship W4254372635A5019398807 @default.
- W4254372635 hasAuthorship W4254372635A5036985768 @default.
- W4254372635 hasAuthorship W4254372635A5039505764 @default.
- W4254372635 hasAuthorship W4254372635A5047149762 @default.
- W4254372635 hasAuthorship W4254372635A5070673623 @default.
- W4254372635 hasAuthorship W4254372635A5074897884 @default.
- W4254372635 hasAuthorship W4254372635A5086979668 @default.
- W4254372635 hasConcept C11960822 @default.
- W4254372635 hasConcept C121608353 @default.
- W4254372635 hasConcept C126322002 @default.
- W4254372635 hasConcept C178666793 @default.
- W4254372635 hasConcept C27740335 @default.
- W4254372635 hasConcept C2777609662 @default.
- W4254372635 hasConcept C2779549131 @default.
- W4254372635 hasConcept C502942594 @default.
- W4254372635 hasConcept C62478195 @default.
- W4254372635 hasConcept C71924100 @default.
- W4254372635 hasConcept C86554907 @default.
- W4254372635 hasConcept C86803240 @default.
- W4254372635 hasConcept C95444343 @default.
- W4254372635 hasConceptScore W4254372635C11960822 @default.
- W4254372635 hasConceptScore W4254372635C121608353 @default.
- W4254372635 hasConceptScore W4254372635C126322002 @default.
- W4254372635 hasConceptScore W4254372635C178666793 @default.
- W4254372635 hasConceptScore W4254372635C27740335 @default.
- W4254372635 hasConceptScore W4254372635C2777609662 @default.
- W4254372635 hasConceptScore W4254372635C2779549131 @default.
- W4254372635 hasConceptScore W4254372635C502942594 @default.
- W4254372635 hasConceptScore W4254372635C62478195 @default.
- W4254372635 hasConceptScore W4254372635C71924100 @default.
- W4254372635 hasConceptScore W4254372635C86554907 @default.
- W4254372635 hasConceptScore W4254372635C86803240 @default.
- W4254372635 hasConceptScore W4254372635C95444343 @default.
- W4254372635 hasIssue "13_Supplement" @default.
- W4254372635 hasLocation W42543726351 @default.
- W4254372635 hasOpenAccess W4254372635 @default.
- W4254372635 hasPrimaryLocation W42543726351 @default.
- W4254372635 hasRelatedWork W2555402586 @default.
- W4254372635 hasRelatedWork W2744966301 @default.
- W4254372635 hasRelatedWork W2783050518 @default.
- W4254372635 hasRelatedWork W2792929645 @default.
- W4254372635 hasRelatedWork W2900464141 @default.
- W4254372635 hasRelatedWork W3032209073 @default.
- W4254372635 hasRelatedWork W3192317526 @default.
- W4254372635 hasRelatedWork W4289705004 @default.
- W4254372635 hasRelatedWork W4320006642 @default.
- W4254372635 hasRelatedWork W2522379078 @default.
- W4254372635 hasVolume "79" @default.
- W4254372635 isParatext "false" @default.
- W4254372635 isRetracted "false" @default.
- W4254372635 workType "article" @default.